




## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 :  A61K 47/48, 39/385		A1	(11) International Publication Number: <b>WO 91/01146</b>  (43) International Publication Date: 7 February 1991 (07.02.91)
(21) International Application Number: PCT/US90/03983 (22) International Filing Date: 16 July 1990 (16.07.90)			(81) Designated States: AT (European patent), AU, BE (European patent), CA, CH (European patent), DE (European patent)*, DK (European patent), ES (European patent), FI, FR (European patent), GB (European patent), IT (European patent), JP, KR, LU (European patent), NL (European patent), NO, SE (European patent).
(30) Priority data: 380,566 14 July 1989 (14.07.89) US			Published <i>With international search report.</i>
(71) Applicant: PRAXIS BIOLOGICS, INC. [US/US]; 300 East River Road, Rochester, NY 14623 (US).			
(72) Inventors: PILLAI, Subramonia ; 286 Vollmer Parkway, Rochester, NY 14623 (US). EBY, Ronald ; 297 West Squire Drive, #3, Rochester, NY 14623 (US).			
(74) Agents: BROOK, David, E. et al.; Hamilton, Brook, Smith & Reynolds, Two Militia Drive, Lexington, MA 02173 (US).			

## (54) Title: CYTOKINE AND HORMONE CARRIERS FOR CONJUGATE VACCINES



## (57) Abstract

This invention pertains to immunogenic conjugates comprising a carbohydrate containing antigen or other antigen bound to or genetically fused with a cytokine, lymphokine, hormone or growth factor having immunomodulating activity, wherein the cytokine, lymphokine, hormone or growth factor is capable of modifying immunogenicity of the carbohydrate containing antigen. The cytokine or lymphokine can be an interleukin or an interferon. The immunogenic conjugate can be used in vaccine and co-vaccine formulations.

## DESIGNATIONS OF "DE"

Until further notice, any designation of "DE" in any international application whose international filing date is prior to October 3, 1990, shall have effect in the territory of the Federal Republic of Germany with the exception of the territory of the former German Democratic Republic.

### FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MC	Monaco
AU	Australia	FI	Finland	MG	Madagascar
BB	Barbados	FR	France	ML	Mali
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BC	Bulgaria	GR	Greece	NL	Netherlands
BJ	Benin	HU	Hungary	NO	Norway
BR	Brazil	IT	Italy	PL	Poland
CA	Canada	JP	Japan	RO	Romania
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	LI	Liechtenstein	SN	Senegal
CM	Cameroon	LK	Sri Lanka	SU	Soviet Union
DE	Germany	LU	Luxembourg	TD	Chad
DK	Denmark			TG	Togo
				US	United States of America

-1-

CYTOKINE AND HORMONE CARRIERS  
FOR CONJUGATE VACCINES

Background of the Art

Cytokines and lymphokines, such as interferons, 5 GM-CSF, IL-1, IL-2, IL-3, IL-4, IL-5, IL-6 and IL-7 have been shown to have different activities in modulating the immune response. Hormones and growth factors also have modulating effects on cells of the immune system and thus can modulate the immune response. Interferons, IL-1 and 10 IL-2 augment proliferation and differentiation of antigen or mitogen stimulated T cells. They also stimulate B cells to grow and generate antibody responses to antigens. Once activated, B cells have been shown to express IL-2 receptors. A number of synthetic and recombinant 15 lymphokines (Nencioni *et al.*, J. Immunol. 139:800-804 (1987); Kronheim *et al.*, U.S. Patent No. 4,801,686; Tagliabue *et al.*, U.S. Patent No. 4,774,320; Fernandes *et al.*, U.S. Patent No. 4,604,377) have been shown to stimulate immune functions. However, inflammatory and 20 toxic effects often accompany immunotherapeutic administration of cytokines or lymphokines to an organism. In addition, these molecules generally have short half lives.

Certain cytokines and lymphokines have been shown to 25 have adjuvant activity thereby enhancing immune response to an antigen. For example, Nakamura *et al.* demonstrated

- 2 -

that interferon-gamma induced a two- to five-fold enhancement of antibody formation to several antigens. Nakamura *et al.*, Nature 307:381-382 (1984). Interleukins have also been shown to enhance an immune response to 5 antigens. Nencioni *et al.*, J. Immunol. 139:800-804 (1987); Howard *et al.*, EP285441.

The stimulation of antibody response to poorly immunogenic thymus-independent antigens such as polysaccharides has been accomplished in recent years by the 10 covalent coupling of polysaccharides onto a strong thymus-dependent protein antigen. A number of proteins such as diphtheria toxoid, tetanus toxoid and a non-toxic variant of diphtheria toxin, CRM<sub>197</sub> are used as carriers for polysaccharides. The immune response is highly 15 variable depending on the type of protein used as carrier.

A number of conjugates have been previously described for stabilizing and solubilizing proteins such as lymphokines. Moreland and Nitecki (U.S. Patent No. 20 4,745,180, May 17, 1988) describe a pharmaceutical composition comprising  $\beta$ -interferon, interleukin-2 or an immunotoxin which is covalently conjugated to a heparin fragment. The conjugate provides a means for solubilizing the protein which is essentially insoluble in its 25 unconjugated form.

Schmidt *et al.* (U.S. Patent No. 4,772,685, September 20, 1988) describe immunogenic conjugates of IL-1 derived peptides to a high molecular weight carrier protein. Conjugates of IL-2 or interferon and a water soluble 30 polymer (polyethylene glycol) have been described (Katre and Knauf, U.S. Patent No. 4,766,106, August 23, 1988,

and WO8700056, January 15, 1987). Similarly, Garman (EP183503, June 4, 1986) describes conjugates of interferon or IL-2 linked to a water soluble polymer for sustained release of the lymphokine. For background on 5 hormones and growth factors and their receptors see, for example, Hill, D.J., J. Reprod. Fertility 85:723-734 (1989); Roupas et al., Mol. Cell. Endocrinol. 61:1-12 (1989).

Summary of the Invention

10 This invention pertains to immunogenic conjugates and vaccine compositions containing the immunogenic conjugate. The conjugates comprise an antigen (not normally associated with the cytokine, lymphokine, hormone or growth factor), especially a carbohydrate 15 containing antigen, bound to a cytokine, lymphokine, hormone or growth factor having immunomodulating activity, wherein the cytokine, lymphokine, hormone or growth factor modifies the immunogenic activity of the antigen. The cytokine or lymphokine can be an interleukin, such as interleukin-1 $\alpha$ , interleukin-1 $\beta$ , interleukin-2, an interferon, such as interferon gamma, or other cytokine or lymphokine which has immunomodulating activity. The hormone or growth factor can be of bovine, porcine or chicken origin, for example, and can be tumor 20 necrosis factor (TNF), prolactin, epidermal growth factor (EGF), tissue growth factor (TGF), granulocyte macrophage colony stimulating factor (GMCSF), granulocyte colony stimulating factor (GCSF), insulin-like growth factor (IGF-1), somatotropin or insulin, or any other hormone or 25 growth factor whose receptor is expressed on cells of the immune system.

The invention further pertains to a method for eliciting an immune response which comprises administering to an animal an immunogenic amount of a vaccine composition comprising the immunogenic conjugate of the present invention in a pharmaceutically acceptable vehicle and an optional adjuvant. The immunogenic conjugate can be admixed with a coadministered antigen which may be a conjugate, complex or mixture from the same or a different organism than that from which the antigen is derived, in a pharmaceutically acceptable vehicle and an optional adjuvant to produce a co-vaccine which can be used to elicit an immune response to both the conjugated antigen and the admixed antigen.

Brief Description of the Figures .

15 Figure 1 shows high pressure liquid chromatographic (HPLC) analysis of unconjugated recombinant human IL-2 (rhIL-2) compared to crude polyribosylribitolphosphate-(PRP)-rhIL-2 conjugates.

20 Figure 2 shows a chromatogram of a PRP-rhIL-2 conjugate in a 2:1 (w/w) ratio of PRP to rhIL-2 in the starting reaction.

25 Figure 3 shows a chromatogram of a mock conjugate of rhIL-2, wherein the conjugation procedure was followed without added PRP.

Figure 4 shows an immunoblot of selected conjugates which were detected with monoclonal antibodies to PRP. From left to right, the lanes contain PRP-CRM, rhIL-2, PRP, PRP-rhIL-2(2X), PRP-rhIL-2(2X), Blank, PRP-rhIL-2(20X), and PRP-rhIL-2(20X).

30 Figure 5a-c show HPLC analyses of (a) unconjugated recombinant bovine IL-2 (BrIL-2), (b) PRP-BrIL-2 (2:1) conjugate and (c) PRP-BrIL-2 (20:1) conjugate.

- 5 -

Figure 6 shows a Western blot analysis of PRP-BrIL-2 vaccine. The blot was developed with a monoclonal anti-PRP antibody (E117-5) or with a polyclonal anti-BrIL-2 antibody as indicated.

5 Figure 7 shows a comparison of the biological activities of BrIL-2 with the PRP-BrIL-2 conjugates in a BT-2 bioassay.

Detailed Description of the Invention

10 This invention pertains to immunogenic conjugates comprising an antigen, particularly a protein, a peptide, an oligo- or polysaccharide or other carbohydrate containing antigen bound to a cytokine, lymphokine, hormone or growth factor. The conjugation of the antigen to the cytokine, lymphokine, hormone or growth factor provides an immunogenic conjugate which can modify the immune response to the antigen. In addition to modified immunogenicity, the antigenic component of the conjugate can stabilize the cytokine, lymphokine, hormone or growth 20 factor.

The cytokine, lymphokine, hormone or growth factor functions to modulate the immune response to the antigen and the latter stabilizes the biological activity of the cytokine, lymphokine, hormone or growth factor. The 25 cytokine, lymphokine, hormone or growth factor can be an interleukin such as interleukin-1 $\alpha$ , interleukin-1 $\beta$ , interleukin-2, an interferon, such as interferon gamma, or other cytokine or lymphokine which has immuno-modulating activity. Portions of cytokines or lymphokines or miteins or mimics having immunomodulating 30

activity can also be used. Preferably, the lymphokine is interleukin-2. The hormone, growth factor or immuno-modulating portions thereof can be of bovine, porcine or chicken origin, for example, and can be tumor necrosis factor (TNF), prolactin, epidermal growth factor (EGF), tissue growth factor (TGF), granulocyte macrophage colony stimulating factor (GMCSF), granulocyte colony stimulating factor (GCSF), insulin-like growth factor (IGF-1), somatotropin (growth hormone) or insulin, or any other hormone or growth factor whose receptor is expressed on cells of the immune system.

Cytokines, lymphokines, hormones or growth factors can be obtained from any suitable source. They can be produced by recombinant DNA methodology. For example, the genes encoding several human interleukins have been cloned and expressed in a variety of host systems, permitting the production of large quantities of pure human interleukin. Further, certain T lymphocyte lines produce high levels of interleukin, thus providing a source of the lymphokine.

The carbohydrate containing antigen or non-carbohydrate antigen can be derived from any source to which an immunogenic response is desired. The carbohydrate containing antigen or other antigen can be one which is not itself immunogenic or weakly so, but can become immunogenic or more so by virtue of conjugation to the cytokine, lymphokine, hormone or growth factor. The carbohydrate containing antigen can be an oligosaccharide, polysaccharide, peptidoglycan and glycopptide. Examples of carbohydrate containing antigens of interest include bacterial capsular polymers, lip polysaccharide or lipopolysaccharide components,

auto-immunity related antigens, allergens, tumor-associated antigens, fungal and viral antigens, hormones and bacterial cell wall components, such as peptidoglycans or fragments thereof.

5 Bacterial capsular polymers, oligomers and fragments thereof are among the groups of antigens which have potential to be effectively employed in a vaccine but which are only weakly immunogenic in young humans. As used in this application, the term "capsular polymers" 10 refers to sugar-containing polymers, such as polymers of sugars, sugar acids, amino sugars, and sugar phosphates. These "capsular polymers" are frequently referred to in the medical literature as "capsular polysaccharides" though they may contain linkages other than glycosidic 15 linkages and constituents other than sugars such as those listed above.

The capsular polymers (CP) can be derived from many different types of bacteria. These types include Haemophilus influenzae, Streptococcus species including 20 pneumoniae (particularly serotypes 1, 4, 5, 6A, 6B, 9V, 14, 18C, 19F, and 23F) pyogenes and agalactiae, Neisseria meningitidis (such as serogroup a, b and c), Klebsiella pneumoniae, Pseudomonas aeruginosa and Staphylococcus aureus.

25 Non-bacterial polymers can be derived from yeast and fungi, for example, Cryptococcus neoformans, or carbohydrate containing units found uniquely on cancer cells or those found associated with allergens.

30 The conjugates of this invention can be prepared by any of the biologically compatible methods known in the art for coupling of carb hydrate containing antigens or

other antigens to carriers. The method of coupling is most preferably covalent coupling whereby the carbohydrate containing antigen or other antigens is bound directly to the cytokine, lymphokine, hormone or growth factor. However, other means by which the antigen is conjugated to the cytokine, lymphokine, hormone or growth factor is included within the scope of the invention. Many such methods are currently available for coupling of carbohydrate containing antigens or other antigens to carriers. Most methods create either amine or amide bonds, or in some cases thio-esters. One particularly preferred method for coupling a carbohydrate containing antigen to the cytokine, lymphokine, hormone or growth factor is by reductive amination which has been described by Anderson, P.W., U.S. Patent No. 4,673,573, issued June 16, 1987, and U.S. Patent No. 4,761,283, issued August 2, 1988, the teachings of which are incorporated herein by reference.

The conjugates of this invention can be used to elicit an immune response to an antigen, such as a carbohydrate containing antigen or saccharide, in a warm-blooded animal. The method comprises administering to the animal, an immunologically effective dose of a conjugate comprising a carbohydrate containing antigen bound to a cytokine, lymphokine, hormone or growth factor in a vaccine composition. The vaccine compositions are useful for the prevention of microbial infections. The conjugates may be administered in a pharmaceutically acceptable vehicle, such as physiological saline, or ethanol polyols (such as glycerol or propylene glycol). The vaccine composition may optionally comprise

adjuvants, such as vegetable oils or emulsions thereof, surface active substances, e.g., hexadecylamine, octadecyl amino acid esters, octadecylamine, lysolecithin, dimethyl-dioctadecylammonium bromide, N,N-dioctadecyl-  
5 N'-N'bis(2-hydroxyethyl-propane diamine), methoxyhexadecylglycerol, and pluronic polyols; polyamines, e.g., pyran, dextransulfate, poly IC, carbopol; peptides, e.g., muramyl dipeptide, dimethylglycine, tuftsin; immune stimulating complexes (ISCOMS); oil emulsions; and  
10 mineral gels. The conjugates of this invention may also be incorporated into liposomes or ISCOMS. Supplementary active ingredients may also be employed. The conjugate can also be adsorbed onto a mineral suspension, such as alum, i.e., aluminum hydroxide or aluminum phosphate to  
15 further modulate the protective immune response to the carbohydrate containing antigen.

The vaccines can be administered to a human or animal in a variety of ways. These include intradermal, transdermal (such as by slow release polymers), intra-  
20 muscular, intraperitoneal, intravenous, subcutaneous, oral and intranasal routes of administration. The amount of conjugate employed in such a vaccine will vary depending upon the identity of the carbohydrate containing antigen or other antigen employed. Adjustment and  
25 manipulation of established dosage ranges used with traditional carrier conjugates for adaptation to the present conjugate vaccines is well within the ability of those skilled in the art. The conjugates of the present invention are intended for use in the treatment of both  
30 immature and adult warm-blooded animals, and in particular humans. Also, the use of the present methods and

-10-

conjugates is not limited to prophylactic applications; therapeutic applications are also contemplated (e.g., AIDS prophylaxis and therapy), as well as immune focusing to alter growth, productivity or reproduction.

5 A vaccine composition which can be useful in the vaccination against meningitis caused by Haemophilus influenzae will comprise the oligomer polyribosyl-ribitolphosphate (PRP) of Haemophilus influenzae type b conjugated to interleukin-2. Bacterial meningitis in the  
10 United States is most commonly caused by H. influenzae type b.

The immunogenic conjugates of the invention can be admixed with an antigenic determinant, or antigen from the same or different organism in a pharmaceutically  
15 acceptable vehicle and an optional adjuvant to produce a co-vaccine which can be used to elicit an immune response to both the conjugated antigen and the admixed non-conjugated antigen.

Suitable antigens which can be used in the co-  
20 vaccine compositions of the invention include particulate antigens, such as those derived from bacteria, viruses, parasites or fungi and microcomponents of cells and soluble antigens, such as proteins, peptides, hormones and glycoproteins. Antigens of particular interest are  
25 viral, fungal, parasite or bacterial antigens, allergens, auto-immunity related antigens, or tumor-associated antigens. The antigens can be obtained from natural sources or they can be produced by recombinant DNA technology or by other artificial means.

30 Among the bacterial antigens of interest are those associated with the human bacterial pathogens including, but not limited to for example, typable and nontypable

Haemophilus influenzae, Escherichia coli, Neisseria meningitidis, Streptococcus pneumoniae, Streptococcus pyogenes, Branhamella catarrhalis, Vibrio cholerae, Corynebacteria diphtheriae, Neisseria gonorrhoeae,

5 Bordetella pertussis, Pseudomonas aeruginosa, Staphylococcus aureus, Klebsiella pneumoniae and Clostridium tetani. Some specific bacterial antigens include bacterial surface and outer membrane proteins (e.g. from Haemophilus influenzae, Neisseria meningitidis, Neisseria gonorrhoeae or Branhamella catarrhalis) and bacterial surface proteins (e.g. the M protein from Streptococcus pyogenes).

Viral antigens from pathogenic viruses include but are not limited to, human immunodeficiency virus (types I and II), human T-cell leukemia virus (types I, II and III), respiratory syncytial virus, hepatitis A, hepatitis B, hepatitis C, non-A and non-B hepatitis virus, herpes simplex virus (types I and II), cytomegalovirus, influenza virus, parainfluenza virus, poliovirus, 20 rotavirus, coronavirus, rubella virus, measles virus, varicella, Epstein Barr virus, adenovirus, papilloma virus and yellow fever virus.

Several specific viral antigens of these pathogenic viruses include the F protein (especially antigens containing the F peptide 283-315, described in WO89/02935 entitled "Respiratory Syncytial Virus: Vaccines and Diagnostic Assays" by Paradiso, P. et al.) and the N and G proteins of respiratory syncytial virus (RSV), VP4 (previously known as VP3), VP6 and VP7 polypeptides of 25 rotavirus, envelope glycoproteins of human immunodeficiency virus and the surface and presurface antigens of hepatitis B and herpes glyc proteins B and D.

Fungal antigen that can be those derived from fungi including but are not limited to Candida spp. (especially albicans), Cryptococcus spp. (especially neoformans), Blastomyces spp. (e.g., dermatitidis), Histoplasma spp. (especially capsulatum), Goccidiroides spp. (especially immitis), Paracoccidioides spp. (especially brasiliensis) and Aspergillus spp. Examples of parasite antigens include but are not limited to Plasmodium spp., Eimeria spp., Schistosoma spp., Trypanosoma spp., Babesia spp., Leishmania spp., Cryptosporidium spp., Toxoplasma spp. and Pneumocystis spp.

Also of interest are various antigens associated with auto-immune diseases, such as rheumatoid arthritis and lupus erythematosus.

The modulation of the immune response has a number of important implications. For example, the adjuvant action of the cytokine, lymphokine, hormone or growth factor can increase the concentration of protective antibodies produced against the antigenic portion of the conjugate in the vaccinated organism. Likewise, antibody production against antigens co-administered with the conjugate can be increased. As a result, effective (i.e., protective) vaccination can be achieved with a smaller quantity of conjugated antigen and/or co-administered antigen than would be normally required. This reduction in the required amount of conjugated antigen and co-administered antigen may lead to more widespread use of vaccines which are difficult or costly to prepare or which are weakly immunogenic. This is especially true in the developing nations which must face such epidemics as malaria and cholera, with very limited health care budgets. It may also provide for safer vaccination when the antigen is toxic at the concentra-

-13-

tion normally required for effective immunization. By reducing the amount of antigen, the risk of toxic reaction is reduced.

Other applications may also include the elicitation 5 of an immune response to stimulate or inhibit the stability or interaction of cellular modifiers, including hormones with their corresponding receptors or binding components. In this fashion, the immune response can be used to inhibit/enhance growth, reproduction, differentiation, 10 and overall performance. Alternatively, the quality of the immune response can be manipulated to optimize the desired protective response.

In a specific embodiment of this invention, IL-2-conjugates have an added advantage; the binding of the 15 carbohydrate containing antigen or other antigen to specific B and T cells focuses the IL-2 into the vicinity of the B and T cell interleukin receptors.

Cytokines, lymphokines, hormones and growth factors by means of their immunomodulating activity, can help 20 evoke a protective immune response against marginally or non-immunogenic conjugated antigens and bound non-conjugated antigens. In this manner, vaccine composition containing fragments of larger proteins, synthetic 25 antigens or products of recombinant DNA technology may be made more potent by mixture with conjugates of the present invention.

Typically, vaccination regimens call for the administration of antigen over a period of weeks or months in order to stimulate a "protective" immune response. A 30 protective immune response, is an immune response sufficient to protect the immunized organism from productive infection by a particular pathogen or pathogens to which the vaccine is directed. Carbohydrate containing anti-

-14-

gens or other antigens, when conjugated to a cytokine, lymphokine, hormone or growth factor and optionally co-administered with antigen from the same or different organism, can modify the generation of a protective 5 immune response. This may reduce the time course of effective vaccination regimens. Further, vaccine formulations comprising the immunogenic conjugates of this invention are stable for a period of time sufficient to allow the manufacture, shipment and storage of the 10 vaccine formulations.

It is to be understood from the above discussion, that the use of the term antigen is meant to imply either the whole antigen or one of its determinants, and is also meant to encompass hapten molecules which could benefit 15 by an increase in the immune response due to the presence of the conjugates of the present invention. The foregoing list of antigens is for exemplary purposes only. Additional antigens which can be used in the co-vaccine compositions of the present invention are readily as- 20 certained by one skilled in the art.

The invention is further illustrated by the following non-limiting Examples:

EXAMPLE 1

PRP-rhIL-2 Conjugates

25 Recombinant human rhIL-2 (1 mg freeze-dried, Cetus, Emeryville, CA) was reconstituted with 300  $\mu$ L of distilled water and divided into 100  $\mu$ L aliquots. Each 100  $\mu$ L aliquot contained 333  $\mu$ g of rhIL-2.

30 Oligosaccharide f PRP (degree of polymerization 20: Dp 20) was coupled onto rhIL-2 at 2:1 r 20:1 weight ratio of PRP to rhIL-2 (in the starting reaction) by

-15-

reductive amination (Anderson, P.W., U.S. Patent No. 4,673,574, issued June 16, 1987, and U.S. Patent No. 4,761,283, issued August 2, 1988) according the following three reaction conditions:

5      Reaction 1

In the first reaction, 100  $\mu$ L of rhIL-2 was mixed with 2 M bicarbonate buffer pH 9.5 (5  $\mu$ L) which brought the reaction mixture to pH 8.5. Sodium cyanoborohydride (57 mg/mL in deionized water, 2  $\mu$ L) was added and the 10 solution stored at 30°C for 24 hours.

Reaction 2

rhIL-2 (100  $\mu$ L, 333  $\mu$ g) was mixed with freeze-dried PRP of Haemophilus influenzae type b oligosaccharide (HbO) (WW-2-65, 600  $\mu$ g). Sodium bicarbonate buffer 2 M 15 pH 9.2 (5  $\mu$ L) was added to make the reaction mixture pH 8.5. Sodium cyanoborohydride (57 mg/mL in deionized water, 2  $\mu$ L) was added and the solution stored at 37°C for 24 hours.

Reaction 3

20      rhIL-2 (100  $\mu$ L, 333  $\mu$ g) was mixed with freeze-dried HbO (WW-2-65, 6.0 mg). Sodium bicarbonate buffer 2 M pH 9.2 (5  $\mu$ L) was added to make the reaction mixture pH 8.5. Sodium cyanoborohydride (57 mg/mL in deionized water, 20 25  $\mu$ L) was added and the solution stored at 37°C for 24 hours.

After 24 hours, each of the reaction mixtures were dialyzed against several changes of saline using an 8,000

MW membrane to remove inorganic ions, such as cyanide. HPLC analysis of the crude reaction mixture on an Ultra-hydrogel (Waters, Milford, MA) columns 125/250 in phosphate buffer showed an increase in size of the 5 protein component (conjugated rhIL-2), as compared to the unconjugated rhIL-2 (Figure 1).

Figure 1 shows an HPLC chromatogram of the crude conjugate mixture of PRP-rhIL-2 in a 20 to 1 ratio of PRP to rhIL-2. The mixture was analyzed on ultrahydrogel 10 column in phosphate buffered saline. Figures 2 and 3 show HPLC chromatograms for PRP-rhIL-2 conjugate in a 2 to 1 ratio of PRP to rhIL-2 and for mock conjugates, respectively.

Crude conjugates were then tested by dot blot 15 analysis for coupling of PRP to rhIL-2 using mouse monoclonal anti-PRP antibody (E117-5; Lab Services, Praxis Biologics, Inc., Rochester, NY). One or two  $\mu$ L of the conjugates was applied on a nitrocellulose paper and air dried for 10 minutes at room temperature. The paper 20 was blocked with BLOTT0 (5% non-fat dry milk in 10 mM sodium phosphate buffered saline pH 7.2, 150 mM NaCl). The blot was reacted with monoclonal anti-PRP antibodies. Following extensive washings with BLOTT0, blots were 25 reacted with HRP-goat anti-mouse antibodies. The blots were developed with a solution containing 0.01% hydrogen peroxide; 0.06% 4-chloro-1-naphthol (Sigma Chemical Co., St. Louis, MO). rhIL-2 or PRP alone did not show any reactivity and PRP-rhIL-2 conjugate showed positive reactivity. Since PRP alone does not bind to nitro- 30 cellulose, the data suggests that PRP is coupled to rhIL-2 (Figure 4).

Biological Activity

Conjugates were stored at 4°C and various days thereafter, rhIL-2 activity was monitored in a biological assay using CTLL cell line obtained from the ATCC. CTLL 5 is a rhIL-2 dependent cell line and the deprivation of rhIL-2 from these cells results in the death of these cells. Briefly,  $5 \times 10^3$  CTLL cells were cultured with various concentrations of rhIL-2 or PRP-rhIL-2. The growth of CTLL was monitored by the incorporation of 10  $[^3\text{H}]\text{-thymidine}$  (Table I).

Table I shows the biological activity of interleukin-2 in various PRP-rhIL-2 conjugates. rhIL-2 and conjugates were titrated at various concentrations into the cultures containing  $3 \times 10^3$  CTLL cells. The growth of 15 cells was measured by the incorporation of  $[^3\text{H}]$ -thymidine. Data are presented as % control response. The stimulation indices are normalized to the values obtained with a standard preparation of rhIL-2. From the data, PRP-rhIL-2 (20X) possess better rhIL-2 activity 20 than PRP-rhIL-2 (2X) or mock rhIL-2 conjugates.

-18-

TABLE I  
 STABILITY OF PRP-rhIL-2 CONJUGATE VACCINE  
 STIMULATION INDEX (Expressed as % Control Response)  
 Days After The Conjugation Reaction

	<u>Stimulator</u>	<u>10</u>	<u>20</u>	<u>40</u>	<u>50</u>	<u>70</u>
5	Mock					
	conjugate	37	1.5	2.5	18	8
	PRP-rhIL-2					
	(2:1)	33	4.9	61	40	17
10	PRP-rhIL-2					
	(20:1)	68	23	86	91	95
	PRP-CRM <sub>197</sub>	0	0	0	0	0
	(HbOC)					

Immunogenicity of PRP-rhIL-2 conjugate vaccines:

15        Swiss-Webster mice (Taconic Farms, Germantown, NY) were immunized with PRP-rhIL-2 (20:1) or PRP-rhIL-2 (2:1) conjugate vaccines. Each vaccine was tested in a group of 5 animals. PRP-CRM<sub>197</sub> conjugate vaccines (HbOC, Praxis Biologics, Inc., Rochester, NY) were used as 20 positive control. PRP-rhIL-2 conjugate vaccines (stored for 135 days at 4°C) were injected intramuscularly into mice in an amount of 10 or 1 µg of rhIL-2 without the use of adjuvant. PRP-CRM<sub>197</sub> was used at 1 µg of PRP per mouse. The mice were then boosted at two weeks using the 25 same dose and route of injection. Serum samples were taken at 0, 2 and 4 weeks, pooled and used to determine antibody response to PRP by Farr assay according to the following procedure:

-19-

Antibody to PRP was determined by a standardized Farr radioimmunoassay. Various dilutions of sera, sera standard and assay controls were prepared in fetal bovine sera and 25  $\mu$ l aliquots transferred, in duplicate, to 1.5 ml Eppendorf tubes.  $[^3\text{H}]\text{-PRP}$  (50  $\mu$ l) with  $[^{36}\text{Cl}]\text{-tracer}$  was added to all tubes. The samples were vortexed and incubated overnight at 4°C. Saturated ammonium sulfate (75  $\mu$ l) was added to all samples after which the samples were vortexed and incubated at 4°C for 40 min. The supernatant was carefully aspirated and 400  $\mu$ l of distilled water was added to all pellets. After vortexing, the entire contents of the vial and the vial itself were placed in a scintillation vial containing 10 ml of scintillation fluid. After vigorous agitation, the vials are counted on a liquid scintillation counter. The concentration of antibody bound to PRP was calculated, in comparison to a known standard.

Table II shows the anti-PRP antibody response elicited in mice immunized with various conjugate vaccines. A primary anti-PRP antibody response varying from 2 to 3.5  $\mu$ g was observed with different vaccines. A boostable response was observed with most of the vaccines on week 4. PRP-rhIL-2 (20:1) induced a response which is comparable to that of Haemophilus influenza type b oligosaccharide CRM<sub>197</sub> conjugate (HbOC).

- 20 -

TABLE II  
 Anti-PRP Antibody Response to PRP-rhIL-2  
 Conjugate Vaccines

Anti-PRP antibody ( $\mu$ g/ml)*					
5	<u>Vaccines</u>	<u>dose (<math>\mu</math>g)</u>	<u>Wk0</u>	<u>Wk2</u>	<u>Wk4</u>
	PRP-rhIL-2 (20:1)	10	0.17	2.0	8.0
	PRP-rhIL-2 (20:1)	1	0.10	2.0	5.37
10	PRP-rhIL-2 (2:1)	10	0.10	3.54	4.19
	PRP-rhIL-2 (2:1)	1	0.14	2.0	4.20
	HbOC	1	0.10	2.0	8.71
15	PRP-rhIL-2 conjugate vaccines were injected based on rhIL-2 concentration and HbOC was used based on PRP concentration.				
20	*Data from previous experiments show that PRP(DP20) alone or PRP mixed with protein do not induce any PRP antibody response.				

-21-

EXAMPLE 2

PRP-BrIL-2 Conjugates

It is possible that the induction of anti-PRP antibody in mice by PRP-rhIL-2 vaccine may be due to the 5 carrier effect of the IL-2, rather than the targeting of PRP to the appropriate B cells. In order to rule out this possibility, this hypothesis was tested in a homologous system. To exemplify this phenomenon, PRP was covalently coupled to recombinant bovine IL-2 (BrIL-2) 10 and this conjugate was tested for immunogenicity in a bovine system.

PRP was coupled to recombinant bovine IL-2 at 2:1 and 20:1 (PRP:IL-2) ratio following the protocol described in Example 1. After 24 hours, conjugates were 15 dialyzed against several changes of saline using an 8,000 MW membrane to remove inorganic ions such as cyanide. The crude mixtures were analyzed by HPLC using Ultra-hydrogel (Waters, Milford, MA) columns 125/250 in phosphate buffer. An increase in the size of the protein 20 component as compared to the unconjugated BrIL-2 suggests a good conjugation (Fig. 5).

Purified conjugates and unconjugated BrIL-2 were evaluated in SDS-PAGE and Western blot. Materials were dissolved in 100  $\mu$ l of a sample buffer (0.2M Tris buffer 25 containing 5% SDS, 0.025% bromophenol blue,  $10^{-1}$  M 2-methanol and 20% glycerol) and heated for 5 min. at 100°C. Analyses were performed using the Bio-Rad mini protein gel system (Redmond, CA). Gels were 1.5 mm thick and the separating gel contained 15% acrylamide with an

acrylamide to bis ratio of 30:0.8 (0.37M Tris-HCl, pH 8.8 and 0.1% SDS). The stacking gel contained 4.8% acrylamide with the same ratio of acrylamide to bis.

5 Ten to fifteen microliters containing 1-10 µg of samples were applied to each lane. Following electrophoresis, gels were stained for at least one hour with 0.125% Coomassie blue in ethanol:acetic acid:water (5:1:5), then destained with the same solvent system without the dye. Pre-stained molecular weight standards 10 were used to assist in the determination of the relative molecular weight of protein. Duplicate gel without staining was used for Western blot analysis. The major band of approximately 16,000 dalton molecular weight was observed in the lane loaded with BrIL-2 alone. The 15 conjugates appear as diffused band at the higher molecular weight region. No evidence of unconjugated BrIL-2 was observed.

Samples separated on PAGE were transferred electrophoretically onto nitrocellulose membranes at 0.45 mAmps 20 for 90 minutes in 25 mM Tris-383 mM glycine pH 8.8 at room temperature. Membranes were soaked in BLOTO (5% non-fat dry milk in phosphate buffered saline) at 37°C for 1 hour. Membranes were probed with a predetermined concentration of a monoclonal anti-PRP antibody (E117-5) 25 or a polyclonal rabbit anti-BrIL-2 for 1 hour at 37°C and washed with BLOTO. Bound antibodies were detected with horseradish peroxidase conjugated secondary antibody (Kirkegaard and Perry, MD) in BLOTO for 1 hour at 37°C. Blots were washed 3-4X with PBS and developed with PBS 30 containing 0.01% hydrogen peroxide; 0.06% 4-chloro-

1-naphthal in methanol for 20 minutes at room temperature. The reaction was stopped by transferring the filters to distilled water and the filters dried by blotting. The data is presented in Figure 6. Anti-PRP 5 antibody reacted with both PRP-BrIL-2 conjugates but did not react with the unconjugated BrIL-2. Molecular weight of the conjugates also increased considerably. Free PRP, when not coupled to any protein, do not adhere to the nitrocellulose membrane. The data suggests that PRP was 10 covalently coupled to BrIL-2.

Anti-BrIL-2 reacted with free IL-2 and IL-2 conjugates. The data is similar to that observed with anti-PRP antibody.

Covalent coupling of PRP onto the IL-2 has been 15 confirmed by amino acid analysis. As saccharides are coupled to the epsilon amino group of lysine residue of the protein, a reduction of lysine and generation of an unique hydroxyethyl lysine residue was monitored. The analysis of the data shows hydroxyethyl lysine demonstrating the covalent coupling of PRP onto the protein. 20

#### Biological Activity

Conjugates were stored at 4°C and the biological activity of the bovine IL-2 was monitored in a bioassay using IL-2 dependent bovine T cell line, BT-2. The 25 deprivation of IL-2 from these cell line results in the death of these cells. Briefly,  $5 \times 10^4$  BT-2 cells were cultured in a 96 well flat-bottom microculture plate in the presence of different concentrations of BrIL-2 or PRP-BrIL-2 conjugates. After 48 hours, 10  $\mu$ l of MTT 30 [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium

bromide] solution was added (5mg/ml of PBS) and mixed 20 times. MTT is cleaved by living cells to yield a dark blue formazan product. The formazan product was quantitated by measuring absorbance at 550 nm by addition 5 of isopropanol. The data are presented in Figure 7. Both 2:1 and 20:1 conjugates retained biological activity which are 100 to 1000 times lower respectively than the unconjugated BrIL-2.

Immunogenicity of PRP-BrIL-2 conjugate vaccine

10 Groups of 3 cows were immunized with the conjugate vaccine. PRP-CRM<sub>197</sub> (HbOC) conjugate vaccines were used as a positive control and PRP mixed with BrIL-2 was used as a negative control. All vaccines were formulated in aluminum phosphate at a concentration of 1 mg/ml. Each 15 animal received 10  $\mu$ g of PRP/dose. Cows were pre-bled to estimate the pre-existing antibody level to PRP and those with high anti-PRP titers were distributed equally between experimental and control groups.

20 Animals were immunized subcutaneously with 10  $\mu$ g of PRP or conjugates in 2 ml volume on week 0 and bled on weeks 1 and 2. A second dose of vaccine was administered on week 2 and blood was collected on weeks 3 and 4. Antibody response to PRP was measured by a standardized Farr radioimmunoassay as previously described.

25 Geometric mean anti-PRP antibody titers are presented in Table III. PRP-IL-2 (2:1) conjugate induced anti-PRP antibodies at week 3 which are 2.3 fold higher than the preimmune antibody level and the PRP-IL-2 (20:1) induced an approximately 3 fold increase in antibodies at week 3.

30 HbOC, human PRP-CRM<sub>197</sub> vaccine formulation, induced a six fold increase in anti-PRP titer at week 3. PRP when

- 25 -

mixed with BrIL-2 did not induce a significant rise in the anti-PRP antibody level. The data suggest that the PRP-IL-2 (2:1) and (20:1) conjugates target the vaccine onto the appropriate lymphocytes to stimulate the  
 5 response.

TABLE III  
 Bovine Anti-PRP Antibody Response  
 to PRP-BrIL-2 Conjugates

		GMT Anti-PRP Antibody ( $\mu$ g/ml)				Fold
		Wk_0	Wk_1	Wk_2	Wk_3	
10	<u>Antigens</u>					
	PRP+IL-2	0.70	0.46	0.54	.46	none
	PRP-CRM <sub>197</sub> (HbOC)	0.38	0.38	0.98	2.3	6.1
15	PRP-IL-2 (20:1)	0.35	0.48	0.55	1.0	2.8
	PRP-IL-2 (2:1)	0.31	0.35	0.36	.71	2.3

-----  
 \*Fold increase at week 3 is expressed as increase over  
 20 the week 0 antibody titer.

- 26 -

Equivalents

Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the 5 invention described specifically herein. Such equivalents are intended to be encompassed in the scope of the following claims:

-27-

CLAIMS

1. An immunogenic conjugate comprising an antigen bound to a cytokine, lymphokine, hormone, growth factor or portion thereof whose receptor is expressed on cells of the immune system, having immunomodulating activity, wherein the antigen is not normally associated with the cytokine, lymphokine, hormone or growth factor.  
5
2. The conjugate of Claim 1, wherein the cytokine or lymphokine is interferon, interleukin-1 $\alpha$ , interleukin-1 $\beta$ , interleukin-2 or portion thereof.  
10
3. The conjugate of Claim 1, wherein the hormone or growth factor is tumor necrosis factor, prolactin, epidermal growth factor, tissue growth factor, granulocyte macrophage colony stimulating factor, granulocyte colony stimulating factor, insulin-like growth factor, somatotropin or insulin.  
15
4. The conjugate of Claim 1, wherein the antigen is covalently bound to the cytokine or hormone.  
20
5. The conjugate of Claim 4, wherein the antigen is bound to the cytokine, lymphokine, hormone or growth factor by reductive amination.
6. The conjugate of Claim 1, wherein the antigen is bound to the cytokine, lymphokine, hormone or growth factor by genetic fusion techniques.  
25

7. The conjugate of Claim 1, wherein the antigen is a viral, bacterial, fungal or parasite antigen of a warm-blooded animal or human pathogen.
8. The conjugate of Claim 1, wherein the antigen is a carbohydrate containing antigen.  
5
9. The conjugate of Claim 8, wherein the carbohydrate containing antigen is an oligosaccharide or polysaccharide.
- 10 10. The conjugate of Claim 1, wherein the antigen is a bacterial capsular polymer, oligomer or fragment thereof.
11. The conjugate of Claim 10, wherein the polymer or oligomer is derived from Haemophilus influenzae,  
15 Escherichia coli, Neisseria meningitidis, Streptococcus pneumoniae, Streptococcus pyogenes,  
Branhamella catarrhalis, Vibrio cholerae, Corynebacteria diphtheriae, Neisseria gonorrhoeae,  
Bordetella pertussis, Pseudomonas aeruginosa,  
20 Staphylococcus aureus, Klebsiella pneumoniae or  
Clostridium tetani.
12. The conjugate of Claim 11, wherein the polymer or oligomer is polyribosylribitolphosphate.
13. The conjugate of Claim 11, wherein the polymer or  
25 oligomer is derived from Streptococcus pneumoniae.

- 29 -

14. The conjugate of Claim 13, wherein the polymer or oligomer is from serotype 1, 4, 5, 6A, 6B, 9V, 14, 18C, 19F or 23F of S. pneumoniae.
15. The conjugate of Claim 10, wherein the polymer or oligomer is from group A or group C capsular saccharide of N. meningitidis.
16. The conjugate of Claim 1, wherein the antigen is a bacterial cell wall peptidoglycan or fragment thereof.
- 10 17. The conjugate of Claim 1, wherein the antigen is a bacterial lipopolysaccharide or component thereof.
18. A vaccine composition, comprising an immunogenic conjugate, comprising an antigen bound to a cytokine, lymphokine, hormone, growth factor or portion thereof whose receptor is expressed on cells of the immune system, having immunomodulating activity, wherein the antigen is not normally associated with the cytokine, lymphokine, hormone or growth factor, in a pharmaceutically acceptable vehicle and an optional adjuvant.
- 15 20 19. The vaccine composition of Claim 18, wherein the cytokine or lymphokine is interferon, interleukin-1 $\alpha$ , interleukin-1 $\beta$ , interleukin-2 or portion thereof.

- 30 -

20. The vaccine composition of Claim 18, wherein the hormone or growth factor is tumor necrosis factor, prolactin, epidermal growth factor, tissue growth factor, granulocyte macrophage colony stimulating factor, granulocyte colony stimulating factor, insulin-like growth factor, somatotropin or insulin.
- 5 21. The vaccine composition of Claim 18, wherein the antigen is a bacterial, fungal, parasite antigen of a warm-blooded animal or human pathogen.
- 10 22. The vaccine composition of Claim 18, wherein the antigen is a carbohydrate containing antigen.
23. The vaccine composition of Claim 22, wherein the antigen is an oligosaccharide or polysaccharide.
- 15 24. The vaccine composition of Claim 23, wherein the antigen is a bacterial capsular polymer, oligomer or fragment thereof.
25. The vaccine composition of Claim 24, wherein the polymer or oligomer is derived from Haemophilus influenzae, Escherichia coli, Neisseria meningitidis, Streptococcus pneumoniae, Streptococcus pyogenes, Branhamella catarrhalis, Vibrio cholerae, Corynebacteria diphtheriae, Neisseria gonorrhoeae, Bordetella pertussis, Pseudomonas aeruginosa, Staphylococcus aureus, Klebsiella pneumoniae or Clostridium tetani.

- 31 -

26. The vaccine composition of Claim 24, wherein the polymer or oligomer is polyribosylribitolphosphate.
27. The vaccine composition of Claim 25, wherein the polymer or oligomer is derived from Streptococcus 5 pneumoniae.
28. The vaccine composition of Claim 27, wherein the polymer or oligomer is from serotype 1, 4, 5, 6A, 6B, 9V, 14, 18C, 19F or 23F of S. pneumoniae.
29. The vaccine composition of Claim 25, wherein the 10 polymer or oligomer is from group A or group C capsular saccharide of N. meningitidis.
30. The vaccine composition of Claim 18, further comprising a mineral suspension of alum.
31. A method of eliciting a protective immune response 15 against an antigen, a weakly immunogenic antigen or a non-immunogenic antigen, comprising administering to a warm-blooded host an effective amount of a vaccine composition comprising an immunogenic conjugate, comprising an antigen bound to a cytokine, 20 lymphokine, hormone, growth factor or portion thereof whose receptor is expressed on cells of the immune system, having immunomodulating activity, wherein the antigen is not normally associated with the cytokine, lymphokine, hormone or growth factor, 25 in a pharmaceutically acceptable vehicle and an optional adjuvant.

32. The method of Claim 31, wherein the cytokine or lymphokine is interferon, interleukin-1 $\alpha$ , interleukin-1 $\beta$ , interleukin-2 or portion thereof.
- 5 33. The method of Claim 31, wherein the hormone or growth factor is tumor necrosis factor, prolactin, epidermal growth factor, tissue growth factor, granulocyte macrophage colony stimulating factor, granulocyte colony stimulating factor, insulin-like growth factor, somatotropin or 10 insulin.
34. The method of Claim 31, wherein the antigen is a carbohydrate containing antigen.
- 15 35. A co-vaccine composition for eliciting a immune response against a conjugated antigen and at least one other antigen, comprising an antigen or fragment thereof, admixed with an immunogenic conjugate, comprising an antigen bound to a cytokine, lymphokine, hormone, growth factor or portion thereof whose receptor is expressed on cells of the immune system, 20 having immunomodulating activity, wherein the antigen is not normally associated with the cytokine, lymphokine, hormone or growth factor, in a pharmaceutically acceptable vehicle and an optional adjuvant.
- 25 36. The co-vaccine composition of Claim 35, wherein the cytokine or lymphokine is interferon, interleukin-1 $\alpha$ , interleukin-1 $\beta$ , interleukin-2 or portion thereof.

37. The co-vaccine composition of Claim 35, wherein the hormone or growth factor is tumor necrosis factor, prolactin, epidermal growth factor, tissue growth factor, granulocyte macrophage colony stimulating factor, granulocyte colony stimulating factor, insulin-like growth factor, somatotropin or insulin.
- 5 38. The co-vaccine composition of Claim 35, wherein the conjugated antigen is a carbohydrate containing antigen.
- 10 39. The co-vaccine composition of Claim 38, wherein the conjugated antigen is a bacterial capsular polymer, oligomer or fragment thereof.
40. The co-vaccine composition of Claim 39, wherein the 15 polymer or oligomer is derived from Haemophilus influenzae, Escherichia coli, Neisseria meningitidis, Streptococcus pneumoniae, Streptococcus pyogenes, Branhamella catarrhalis, Vibrio cholerae, Corynebacteria diphtheriae, Neisseria gonorrhoeae, Bordetella pertussis, Pseudomonas aeruginosa, Staphylococcus aureus, Klebsiella pneumoniae or Clostridium tetani.
- 20 41. The co-vaccine composition of Claim 40, wherein the polymer or oligomer is polyribosylribitolphosphate.
- 25 42. The co-vaccine composition of Claim 40, wherein the polymer or ligomer is derived from Streptococcus pneumoniae.

- 34 -

43. The co-vaccine composition of Claim 42, wherein the polymer or oligomer is from serotype 1, 4, 5, 6A, 6B, 9V, 14, 18C, 19F or 23F of S. pneumoniae.
44. The co-vaccine composition of Claim 40, wherein the polymer or oligomer is from group A or group C capsular saccharide of N. meningitidis.
45. The co-vaccine composition of Claim 35, wherein the antigen is a bacterial cell wall peptidoglycan or fragment thereof.
46. The co-vaccine composition of Claim 35, wherein the antigen is a bacterial lipopolysaccharide or component thereof.
47. The co-vaccine composition of Claim 35, wherein the antigen is selected from the group consisting of microbial antigens, viral antigens, parasitic antigens, tumor antigens, allergens, hormones, receptors, binding proteins, self-antigens and autoimmunity-related antigens.
48. The co-vaccine composition of Claim 47, wherein the antigen is a bacterial surface or outer membrane protein or portion thereof.

49. The co-vaccine composition of Claim 48, wherein the antigen is a bacterial outer membrane protein or portion thereof of Haemophilus influenzae, Escherichia coli, Neisseria meningitidis, Streptococcus pneumoniae, Streptococcus pyogenes, Branhamella catarrhalis, Vibrio cholerae, Corynebacteria diphtheriae, Neisseria gonorrhoeae, Bordetella pertussis, Pseudomonas aeruginosa, Staphylococcus aureus, Klebsiella pneumoniae or Clostridium tetani.
50. The co-vaccine composition of Claim 48, wherein the bacterial surface protein is the M protein of Streptococcus pyogenes.
51. The co-vaccine composition of Claim 47, wherein the antigen is the F, N or G protein of respiratory syncytial virus.
52. The co-vaccine composition of Claim 51, wherein the antigen is the peptide 283-315 of protein F of respiratory syncytial virus.
- 20 53. The co-vaccine composition of Claim 35, further comprising a mineral suspension of alum.
54. An immunogenic conjugate comprising polyribosyl-ribitolphosphate bound to interleukin-2, wherein interleukin-2 is capable of modifying the immunogenic activity of polyribosylribitolphosphate.

- 36 -

55. A vaccine composition comprising an immunogenic conjugate comprising polyribosylribitolphosphate bound to interleukin-2, wherein interleukin-2 is capable of modifying the immunogenic activity of polyribosylribitolphosphate, in a pharmaceutically acceptable vehicle and an optional adjuvant.

1/8




FIG. I

SUBSTITUTE SHEET

2/8




FIG. 2

**SUBSTITUTE SHEET**




FIG. 3

## **SUBSTITUTE SHEET**

1	2	3	4	5	6	7	8
o		4/8	•	•		o	o

- |                   |                   |
|-------------------|-------------------|
| 1. PRP-CRM        | 2. IL-2 only      |
| 3. PRP only       | 4. PRP-IL-2 (2X)  |
| 5. PRP-IL-2 (2X)  | 6. —              |
| 7. PRP-IL-2 (20X) | 8. PRP-IL-2 (20X) |

FIG. 4




FIG. 5a  
SUBSTITUTE SHEET




FIG. 5b

**SUBSTITUTE SHEET**





FIG. 5c

SUBSTITUTE SHEET

7/8

1 2 3 4 5 6 7 8 9 10



Probed with monoclonal anti-PRP

- 1) Blank
- 2) Low molecular weight marker
- 3) Bovine rIL-2
- 4) PRP-IL-2 (20:1)
- 5) PRP-IL-2 (2:1)

Probed with polyclonal rabbit anti-BrIL-2

- 6) Low molecular weight marker
- 7) Bovine rIL-2
- 8) PRP-IL-2 (20:1)
- 9) PRP-IL-2 (2:1)
- 10) Blank

**FIG. 6**

**SUBSTITUTE SHEET**




FIG. 7

SUBSTITUTE SHEET

# INTERNATIONAL SEARCH REPORT

International Application No PCT/US 90/03983

<b>I. CLASSIFICATION OF SUBJECT MATTER</b> (if several classification symbols apply, indicate all) <sup>6</sup>														
According to International Patent Classification (IPC) or to both National Classification and IPC														
IPC <sup>5</sup> A 61 K 47/48, A 61 K 39/385														
<b>II. FIELDS SEARCHED</b>														
Minimum Documentation Searched <sup>7</sup>														
<table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 30%;">Classification System</th> <th style="width: 70%;">Classification Symbols</th> </tr> </thead> <tbody> <tr> <td style="text-align: center;">IPC<sup>5</sup></td> <td style="text-align: center;">A 61 K, C 07 K</td> </tr> </tbody> </table>			Classification System	Classification Symbols	IPC <sup>5</sup>	A 61 K, C 07 K								
Classification System	Classification Symbols													
IPC <sup>5</sup>	A 61 K, C 07 K													
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched <sup>8</sup>														
<b>III. DOCUMENTS CONSIDERED TO BE RELEVANT</b>														
<table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 10%;">Category <sup>9</sup></th> <th style="width: 80%;">Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup></th> <th style="width: 10%;">Relevant to Claim No. <sup>13</sup></th> </tr> </thead> <tbody> <tr> <td style="text-align: center;">P,X</td> <td style="text-align: center;">WO, A, 89/12458 (CELL MED, INC.) 28 December 1989 see page 1, paragraph 1 - page 7, paragraph 5; page 28, paragraph 3 - page 29, paragraph 2; page 38, paragraph 2; page 45 - page 49, example 4; claims 1-6  --</td> <td style="text-align: center;">1-30,35-55</td> </tr> <tr> <td style="text-align: center;">Y</td> <td style="text-align: center;">WO, A, 88/06843 (IMMUNEX CORPORATION) 22 September 1988 see page 1, line 6 - page 2, line 11; page 13, lines 17-32  --</td> <td style="text-align: center;">1-30,35-55</td> </tr> <tr> <td style="text-align: center;">Y</td> <td style="text-align: center;">EP, A, 0098581 (CONNAUGHT LABORATORIES) 18 January 1984 see page 1, paragraphs 1,2; page 2, paragraph 3 - page 5, paragraph 2  --</td> <td style="text-align: center;">1-30,35-55 ./.</td> </tr> </tbody> </table>			Category <sup>9</sup>	Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup>	Relevant to Claim No. <sup>13</sup>	P,X	WO, A, 89/12458 (CELL MED, INC.) 28 December 1989 see page 1, paragraph 1 - page 7, paragraph 5; page 28, paragraph 3 - page 29, paragraph 2; page 38, paragraph 2; page 45 - page 49, example 4; claims 1-6  --	1-30,35-55	Y	WO, A, 88/06843 (IMMUNEX CORPORATION) 22 September 1988 see page 1, line 6 - page 2, line 11; page 13, lines 17-32  --	1-30,35-55	Y	EP, A, 0098581 (CONNAUGHT LABORATORIES) 18 January 1984 see page 1, paragraphs 1,2; page 2, paragraph 3 - page 5, paragraph 2  --	1-30,35-55 ./.
Category <sup>9</sup>	Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup>	Relevant to Claim No. <sup>13</sup>												
P,X	WO, A, 89/12458 (CELL MED, INC.) 28 December 1989 see page 1, paragraph 1 - page 7, paragraph 5; page 28, paragraph 3 - page 29, paragraph 2; page 38, paragraph 2; page 45 - page 49, example 4; claims 1-6  --	1-30,35-55												
Y	WO, A, 88/06843 (IMMUNEX CORPORATION) 22 September 1988 see page 1, line 6 - page 2, line 11; page 13, lines 17-32  --	1-30,35-55												
Y	EP, A, 0098581 (CONNAUGHT LABORATORIES) 18 January 1984 see page 1, paragraphs 1,2; page 2, paragraph 3 - page 5, paragraph 2  --	1-30,35-55 ./.												
<p style="margin-left: 20px;">* Special categories of cited documents: to "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed</p> <p style="margin-left: 20px;">"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "A" document member of the same patent family</p>														
<b>IV. CERTIFICATION</b>														
<p>Date of the Actual Completion of the International Search</p> <p style="text-align: center;">20th September 1990</p>		<p>Date of Mailing of this International Search Report</p> <p style="text-align: center;">30 OCT 1990</p>												
<p>International Searching Authority</p> <p style="text-align: center;">EUROPEAN PATENT OFFICE</p>		<p>Signature of Authorized Officer</p> <p style="text-align: center;">MISS D. S. KOWALCZYK</p>												

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category *	Citation of Document, ** with indication, where appropriate, of the relevant passages	Relevant to Claim No.
Y	US, A, 4673574 (P.W. ANDERSON) 16 June 1987 see column 2, line 50 - column 3, line 39; column 4, lines 25-63; claims (cited in the application)  --	1-30,35-55
Y	The Journal of Immunology, vol. 139, no. 3, 1 August 1987, The American Association of Immunologists, Baltimore, (US), L. Nencioni et al.: "In vivo immunostimulating activity of the 163-171 peptide of human IL-1beta", pages 800-804, see page 800, abstract; page 803, paragraph 3 (cited in the application)	1-30,35-55
-----		

**FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET**

**V.  OBSERVATIONS WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE<sup>1</sup>**

This International search report has not been established in respect of certain claims under Article 17(2) (a) for the following reasons:

1.  Claim numbers ..... \* because they relate to subject matter not required to be searched by this Authority, namely:

\* claims no. 31-34  
see PCT Rule 39.1 (iv)

2.  Claim numbers ..... because they relate to parts of the International application that do not comply with the prescribed requirements to such an extent that no meaningful International search can be carried out, specifically:

3.  Claim numbers....., because they are dependent claims and are not drafted in accordance with the second and third sentences of PCT Rule 6.4(a).

**VI.  OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING<sup>2</sup>**

This International Searching Authority found multiple inventions in this International application as follows:

1.  As all required additional search fees were timely paid by the applicant, this International search report covers all searchable claims of the International application.

2.  As only some of the required additional search fees were timely paid by the applicant, this International search report covers only those claims of the International application for which fees were paid, specifically claims:

3.  No required additional search fees were timely paid by the applicant. Consequently, this International search report is restricted to the invention first mentioned in the claims; it is covered by claim numbers:

4.  As all searchable claims could be searched without effort justifying an additional fee, the International Searching Authority did not invite payment of any additional fee.

**Remark on Protest**

- The additional search fees were accompanied by applicant's protest.
- No protest accompanied the payment of additional search fees.

**ANNEX TO THE INTERNATIONAL SEARCH REPORT**  
**ON INTERNATIONAL PATENT APPLICATION NO. US 9003983**  
**SA 38836**

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on 23/10/90. The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO-A- 8912458	28-12-89	AU-A-	3777989	12-01-90
WO-A- 8806843	22-09-88	US-A-	4879374	07-11-89
		AU-A-	1426488	10-10-88
		EP-A-	0349569	10-01-90
EP-A- 0098581	18-01-84	US-A-	4496538	29-01-85
		AU-B-	561978	21-05-87
		AU-A-	1822783	08-02-84
		CA-A-	1210695	02-09-86
		WO-A-	8400300	02-02-84
		US-A-	4619828	28-10-86
		US-A-	4644059	17-02-87
US-A- 4673574	16-06-87	US-A-	4762713	09-08-88
		US-A-	4761283	02-08-88
		US-A-	4902506	20-02-90